Giacomo Pelizzari

List of Publications by Year
in descending order

63	615	566801	610482
papers	citations	15	24
		h-index	g-index

64	64	64	1141
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside. Cancers, 2019, 11, 857.	1.7	77
2	The <scp>IMPACT</scp> study: early loss of skeletal muscle mass in advanced pancreatic cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 368-377.	2.9	61
3	Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors. International Journal of Molecular Sciences, 2019, 20, 3390.	1.8	48
4	Do platinum salts fit all triple negative breast cancers?. Cancer Treatment Reviews, 2016, 48, 34-41.	3.4	46
5	Androgen receptor in estrogen receptor positive breast cancer: Beyond expression. Cancer Treatment Reviews, 2017, 61, 15-22.	3.4	43
6	Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker. Cancers, 2019, 11, 1243.	1.7	40
7	Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle. Expert Opinion on Biological Therapy, 2017, 17, 365-374.	1.4	27
8	Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application. PLoS ONE, 2020, 15, e0228822.	1.1	26
9	Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation. Cancer Treatment Reviews, 2019, 72, 7-14.	3.4	25
10	The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer. Oncologist, 2020, 25, 661-668.	1.9	21
11	Central nervous system involvement in breast cancer patients: Is the therapeutic landscape changing too slowly?. Cancer Treatment Reviews, 2016, 46, 80-88.	3.4	18
12	Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis. Scientific Reports, 2020, 10, 7010.	1.6	18
13	Atezolizumab for the treatment of breast cancer. Expert Opinion on Biological Therapy, 2018, 18, 595-603.	1.4	17
14	Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. International Journal of Molecular Sciences, 2020, 21, 3805.	1.8	17
15	Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study. Clinical Nutrition, 2021, 40, 286-294.	2.3	17
16	A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1185, 122985.	1.2	16
17	Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy. Future Oncology, 2018, 14, 849-859.	1.1	14
18	First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study. Breast, 2021, 57, 104-112.	0.9	14

#	Article	IF	Citations
19	Prognostic role of disease extent and lymphocyte–monocyte ratio in advanced melanoma. Melanoma Research, 2019, 29, 510-515.	0.6	12
20	Immunotherapy in NSCLC Patients with Brain Metastases. International Journal of Molecular Sciences, 2022, 23, 7068.	1.8	12
21	Immunotherapy for older patients with melanoma: From darkness to light?. Pigment Cell and Melanoma Research, 2021, 34, 550-563.	1.5	11
22	An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project. BMC Cancer, 2018, 18, 932.	1.1	6
23	Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer. Cancers, 2021, 13, 3504.	1.7	5
24	Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey. Breast, 2018, 40, 45-52.	0.9	4
25	Feasibility and Predictive Performance of a Triage System for Patients with Cancer During the COVID‑19 Pandemic. Oncologist, 2021, 26, e694-e703.	1.9	3
26	Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma. Annals of Oncology, 2017, 28, vi68.	0.6	2
27	Hype or hope? The strange case of platinum salts' renaissance in breast cancer. Expert Review of Anticancer Therapy, 2019, 19, 1005-1008.	1.1	2
28	Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study. Future Oncology, 2020, 16, 2059-2073.	1.1	2
29	Prognostic role of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) in metastatic breast cancer (MBC) patients: First clues for cost-effective biomarkers.. Journal of Clinical Oncology, 2018, 36, e13079-e13079.	0.8	2
30	A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients. Annals of Oncology, 2018, 29, viii96.	0.6	1
31	Impact of sarcopenia in patients with metastatic melanoma treated with immunotherapy. Annals of Oncology, 2019, 30, v558.	0.6	1
32	Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer. Future Oncology, 2020, 16, 2645-2660.	1.1	1
33	Platinum-Based Chemotherapy in Older Patients with Non-Small Cell Lung Cancer: What to Expect in the Real World. Drugs and Aging, 2020, 37, 677-689.	1.3	1
34	Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive (PS) recurrent ovarian cancer (rOC)? A network meta-analysis (NMA).. Journal of Clinical Oncology, 2019, 37, 5564-5564.	0.8	1
35	Association of clinical factors and biological subtypes with different Ca15-3 levels in metastatic breast cancer.. Journal of Clinical Oncology, 2018, 36, e24014-e24014.	0.8	1
36	Lung cancer patients and unplanned presentations to hospital: insights from a single institution experience. Annals of Oncology, 2016, 27, iv14.	0.6	0

#	Article	IF	Citations
37	Management optimization of non small cell lung cancer (NSCLC) specimens. A single institution experience with a multiplexed mass spectrometry approach. Annals of Oncology, 2016, 27, vi551.	0.6	0
38	Last-line treatment of luminal metastatic breast cancer: which factors influence the therapeutic choice?. Annals of Oncology, 2016, 27, iv63.	0.6	0
39	Treatment strategies in patients with Metastatic Breast Cancer: real-world practice in the United Kingdom (UK) and Italy. Annals of Oncology, 2016, 27, iv63.	0.6	0
40	Final results from CAMEO-PRO study: complementary and alternative medicine in oncology. physicians inform oncological patients. Annals of Oncology, 2017, 28, vi94.	0.6	0
41	Small luminal-like breast cancer: determinants of adjuvant chemotherapy use. Annals of Oncology, 2017, 28, vi33.	0.6	0
42	Strategy of monitoring metastatic breast cancer (M-MBC) in clinical practice: more or less intensive?. Annals of Oncology, 2017, 28, vi30.	0.6	0
43	First-line platinum-based chemotherapy in elderly patients with NSCLC: determinants of therapeutic choice and outcome. Annals of Oncology, 2017, 28, vi61.	0.6	0
44	Monocyte-to-lymphocyte ratio in metastatic colorectal cancer: Prognostic role evaluation and cut-off definition. Annals of Oncology, 2018, 29, viii180.	0.6	0
45	The SENECA study: Prognostic role of serum biomarkers in elderly metastatic colorectal cancer patients. Annals of Oncology, 2018, 29, viii197.	0.6	0
46	Determinants of oncologist's choice in offering drug holidays during first line therapy for patients with metastatic colorectal cancer. Annals of Oncology, 2018, 29, viii197-viii198.	0.6	0
47	The SLICE study: The prognostic role of visceral fat in metastatic colorectal cancer. Annals of Oncology, 2018, 29, viii193.	0.6	0
48	The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA). Annals of Oncology, 2019, 30, iv79.	0.6	0
49	Clinical decision making and multidisciplinary team meetings (MDMs) in early breast cancer. Is the agreement between planned and applied therapeutic program?. Annals of Oncology, 2019, 30, v78.	0.6	0
50	A multivariate model to define prognostic groups among patients with melanoma brain metastases: A 10-year retrospective cohort study. Annals of Oncology, 2019, 30, v556.	0.6	0
51	SUN-PO094: The Role of Nutritional Interventions in Surgically Treated Pancreatic Cancer Patients: Comparative Efficacy in a Network Meta-Analysis (NMA). Clinical Nutrition, 2019, 38, S93-S94.	2.3	0
52	NON-ALCOHOLIC FATTY LIVER DISEASE AND CARDIOVASCULAR RISK. Journal of Hypertension, 2019, 37, e304.	0.3	0
53	Risk of unplanned presentations and hospital admission in lung cancer patients: Insights from the experience of a single institution.. Journal of Clinical Oncology, 2016, 34, e21601-e21601.	0.8	0
54	Screening with low-dose computed tomography (LDCT) of asbestos-exposed subjects and lung cancer (LC) mortality.. Journal of Clinical Oncology, 2016, 34, 1554-1554.	0.8	0

#	Article	IF	Citations
55	Determinants of adjuvant chemotherapy use in small luminal-like breast cancer.. Journal of Clinical Oncology, 2017, 35, e12010-e12010.	0.8	0
56	A novel MGMT methylation-based prognostic score in patients with glioblastoma.. Journal of Clinical Oncology, 2017, 35, 2048-2048.	0.8	0
57	Preliminary results from CAMEO-PRO study: Complementary and alternative medicine in oncologyâ€"Physicians inform oncological patients.. Journal of Clinical Oncology, 2017, 35, e21632-e21632.	0.8	0
58	Integration of lymphocyte ratios (LRs) and circulating tumor cells (CTCs) characterization: The interplay between immunity and metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2018, 36, 12039-12039.	0.8	0
59	Role of anthracyclines in neoadjuvant anti-HER2 regimens for HER2+ breast cancer (BC): A network meta-analysis (NMA).. Journal of Clinical Oncology, 2019, 37, 577-577.	0.8	0
60	Title is missing!. , 2020, 15, e0228822.		0
61	Title is missing!. , 2020, 15, e0228822.		0
62	Title is missing!. , 2020, 15, e0228822.		0
63	Title is missing!. , 2020, 15, e0228822.		0